Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert CofiledCriticalWarner Lambert Co
Priority to CR7060ApriorityCriticalpatent/CR7060A/en
Publication of CR7060ApublicationCriticalpatent/CR7060A/en
Organic Low-Molecular-Weight Compounds And Preparation Thereof
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Se proporcionan compuestos conjugados de pregabalina-lactosa, tambien se proporciona como parte de la presente invencion un nuevo metodo para tratar en un sujeto trastornos o enfermedades del sistema nervioso central, que incluyen trastornos o crisis convulsivas, dolor, depresion, ansiedad, trastornos del sueno, trastornos consuntivos, psicosis, discinesia tardia, enfermedades de Huntington o Parkinson, administrando al sujeto una cantidad farmaceuticamente eficaz de un conjugado de pregabalina lactosa.Conjugated pregabalin-lactose compounds are provided, a new method for treating a central nervous system disorder or disorder, including seizure disorders or seizures, pain, depression, anxiety, sleep disorders, is also provided as part of the present invention. , consumptive disorders, psychosis, tardive dyskinesia, Huntington's or Parkinson's diseases, administering to the subject a pharmaceutically effective amount of a pregabalin lactose conjugate.
APPLICATION OF REVERSE AGONISTS OF THE GUMKA IN COMBINATION WITH PARTIAL AGONISTS OF NICOTINE RECEPTORS, ESTROGEN, ELECTORAL MODULATORS OF ESTROGEN OR VITAMIN E FOR TREATMENT OF COGNITIVE RADIATION.
compound, pharmaceutical composition, and methods for treating or preventing cancer, wet-type macular degeneration or rheumatoid arthritis, aberrant vascularization, excess copper levels, obesity, and neurodegenerative disease in a patient